{"title": "Doen\u00e7as card\u00edacas: tratamentos lideraram vendas em 2017", "author": null, "url": null, "hostname": null, "description": null, "sitename": "PRAIS 2.0", "date": "2012-02-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "[Doen\u00e7as card\u00edacas: tratamentos lideraram vendas em 2017](https://prais.paho.org/es/doencas-cardiacas-tratamentos-lideraram-vendas-em-2017/) [http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/5139611](http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/5139611) [http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/5139611](http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/5139611) [http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/5138381](http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/5138381) [http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/5138381](http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/5138381)\nFDA\u2019s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all health care professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!\nOn Monday, December 10, 2018, at 1pm (EDT), CDER\u2019s Office of Communication, Division of Drug Information (DDI) hosted a webinar titled: FDA Drug Topics: Biosimilar and Interchangeable Products in the U.S.: Scientific Concepts, Clinical Use, and Practical Considerations. This webinar will provide an overview of biosimilar and interchangeable products and the approval process in the U.S. This webinar will also explain the various scientific concepts used in the development of biosimilar products and the FDA\u2019s approval standards. In addition, we will describe some practical information regarding use of these products, such as labeling, terminology, and pharmacy substitution and review the resources available to health care professionals about biosimilar and interchangeable products.\nFor more information go to\n[https://www.fda.gov/AboutFDA/WorkingatFDA/FellowshipInternshipGraduateFacultyPrograms/PharmacyStudentExperientialProgramCDER/ucm626386.htm](https://www.fda.gov/AboutFDA/WorkingatFDA/FellowshipInternshipGraduateFacultyPrograms/PharmacyStudentExperientialProgramCDER/ucm626386.htm)\nLa Secretar\u00eda de Salud a trav\u00e9s de la Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (COFEPRIS), anunci\u00f3 la primera liberaci\u00f3n de 38 productos con cannabis y sus derivados, que no tienen THC ni causan efectos psicoactivos, y estar\u00e1n disponibles en el mercado mexicano, a partir de las siguientes cinco semanas.\nA la par se lanza una campa\u00f1a de concientizaci\u00f3n en las redes sociales sobre el uso adecuado de productos con cannabis y los afectos a la salud, en especial en poblaci\u00f3n infantil, donde presentar\u00e1n detalles cient\u00edficos y m\u00e9dicos relacionados con este tipo de plantas.\nM\u00e1s informaciones por el enlace:\n[https://www.gob.mx/cofepris/articulos/liberan-38-productos-con-cannabis-y-sus-derivados-182739?idiom=es](https://www.gob.mx/cofepris/articulos/liberan-38-productos-con-cannabis-y-sus-derivados-182739?idiom=es)\nLa ANMAT invita al 3er Simposio Argentino de Buenas Pr\u00e1cticas de Farmacovigilancia a realizarse el 28 de noviembre en la Ciudad de Buenos Aires. El mismo est\u00e1 dirigido a la industria farmac\u00e9utica nacional y multinacional, efectores perif\u00e9ricos del Sistema Nacional de Farmacovigilancia, organizaciones de investigaci\u00f3n por contrato (CRO), organizaciones de pacientes, profesionales de la salud, universidades y estudiantes.\nM\u00e1s informaciones por el enlace\n[https://www.argentina.gob.ar/noticias/3er-simposio-argentino-de-buenas-practicas-de-farmacovigilancia](https://www.argentina.gob.ar/noticias/3er-simposio-argentino-de-buenas-practicas-de-farmacovigilancia)\nHuman placenta products for consumption not authorized in Canada, may pose serious health risks\n[https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/68368a-eng.php](https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/68368a-eng.php)\nEficacia y seguridad de ibrutinib en el tratamiento de pacientes con diagn\u00f3stico de linfoma de c\u00e9lulas del manto, con al menos dos l\u00edneas de tratamiento previo\n[http://sites.bvsalud.org/redetsa/brisa/resource/?id=biblioref.referencesource.965704](http://sites.bvsalud.org/redetsa/brisa/resource/?id=biblioref.referencesource.965704)\nEficacia y seguridad de l-asparaginasa e. Coli pegilada en el tratamiento de pacientes con leucemia linfobl\u00e1stica aguda que presentan hipersensibilidad a l- asparaginasa e. Coli nativa, en el contexto de no disponibilidad de l-asparaginasa erwinia\n[http://sites.bvsalud.org/redetsa/brisa/resource/?id=biblioref.referencesource.965705](http://sites.bvsalud.org/redetsa/brisa/resource/?id=biblioref.referencesource.965705)", "language": null, "image": null, "pagetype": null, "links": ["https://prais.paho.org/es/inicio/", "https://prais.paho.org/es/sobre-la-plataforma/", "https://prais.paho.org/es/enlaces-de-interes/", "https://prais.paho.org/es/comentario/", "https://prais.paho.org/en/author/freitasmpaho-org/", "https://prais.paho.org/es/author/freitasmpaho-org/", "https://prais.paho.org/pt/author/freitasmpaho-org/", "http://prais.paho.org/stage/", "https://prais.paho.org/es/inicio/", "https://prais.paho.org/es/inicio/wp-admin/nav-menus.php", "https://prais.paho.org/es/inicio/", "https://prais.paho.org/es/author/freitasmpaho-org/", "#content", "https://prais.paho.org/en/category/rss/", "https://prais.paho.org/es/category/rss-es/", "https://prais.paho.org/pt/category/rss-pt/", "https://prais.paho.org/es/doencas-cardiacas-tratamentos-lideraram-vendas-em-2017/", "https://www.facebook.com/sharer/sharer.php?u=https://prais.paho.org/es/doencas-cardiacas-tratamentos-lideraram-vendas-em-2017/", "https://twitter.com/share?text=Doen\u00e7as card\u00edacas: tratamentos lideraram vendas em 2017&url=https://prais.paho.org/es/doencas-cardiacas-tratamentos-lideraram-vendas-em-2017/", "https://www.linkedin.com/shareArticle?mini=true&url=https://prais.paho.org/es/doencas-cardiacas-tratamentos-lideraram-vendas-em-2017/%26source=", "https://plus.google.com/share?url=https://prais.paho.org/es/doencas-cardiacas-tratamentos-lideraram-vendas-em-2017/", "http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/5139611", "https://prais.paho.org/en/category/rss/", "https://prais.paho.org/es/category/rss-es/", "https://prais.paho.org/pt/category/rss-pt/", "https://prais.paho.org/es/isp-participo-en-el-foro-de-cooperacion-entre-corea-y-chile-para-la-industria-de-la-salud/", "https://www.facebook.com/sharer/sharer.php?u=https://prais.paho.org/es/isp-participo-en-el-foro-de-cooperacion-entre-corea-y-chile-para-la-industria-de-la-salud/", "https://twitter.com/share?text=ISP particip\u00f3 en el Foro de Cooperaci\u00f3n entre Corea y Chile para la Industria de la Salud&url=https://prais.paho.org/es/isp-participo-en-el-foro-de-cooperacion-entre-corea-y-chile-para-la-industria-de-la-salud/", "https://www.linkedin.com/shareArticle?mini=true&url=https://prais.paho.org/es/isp-participo-en-el-foro-de-cooperacion-entre-corea-y-chile-para-la-industria-de-la-salud/%26source=", "https://plus.google.com/share?url=https://prais.paho.org/es/isp-participo-en-el-foro-de-cooperacion-entre-corea-y-chile-para-la-industria-de-la-salud/", "http://www.ispch.cl/noticia/27429", "https://prais.paho.org/en/category/rss/", "https://prais.paho.org/es/category/rss-es/", "https://prais.paho.org/pt/category/rss-pt/", "https://prais.paho.org/es/acompanhe-o-webinar-desta-quinta-feira/", "https://www.facebook.com/sharer/sharer.php?u=https://prais.paho.org/es/acompanhe-o-webinar-desta-quinta-feira/", "https://twitter.com/share?text=Acompanhe o Webinar desta quinta-feira&url=https://prais.paho.org/es/acompanhe-o-webinar-desta-quinta-feira/", "https://www.linkedin.com/shareArticle?mini=true&url=https://prais.paho.org/es/acompanhe-o-webinar-desta-quinta-feira/%26source=", "https://plus.google.com/share?url=https://prais.paho.org/es/acompanhe-o-webinar-desta-quinta-feira/", "http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/5138381", "https://prais.paho.org/en/category/rss/", "https://prais.paho.org/es/category/rss-es/", "https://prais.paho.org/pt/category/rss-pt/", "https://prais.paho.org/es/webinar-discute-uso-de-dados-pela-vigilancia-sanitaria/", "https://www.facebook.com/sharer/sharer.php?u=https://prais.paho.org/es/webinar-discute-uso-de-dados-pela-vigilancia-sanitaria/", "https://twitter.com/share?text=Webinar discute uso de dados pela Vigil\u00e2ncia Sanit\u00e1ria&url=https://prais.paho.org/es/webinar-discute-uso-de-dados-pela-vigilancia-sanitaria/", "https://www.linkedin.com/shareArticle?mini=true&url=https://prais.paho.org/es/webinar-discute-uso-de-dados-pela-vigilancia-sanitaria/%26source=", "https://plus.google.com/share?url=https://prais.paho.org/es/webinar-discute-uso-de-dados-pela-vigilancia-sanitaria/", "http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/5138381", "https://prais.paho.org/es/category/inicio-mensajes/", "https://prais.paho.org/es/fda-drug-topics-biosimilar-and-interchangeable-products-in-the-u-s-scientific-concepts-clinical-use-and-practical-considerations-december-10-2018/", "https://www.facebook.com/sharer/sharer.php?u=https://prais.paho.org/es/fda-drug-topics-biosimilar-and-interchangeable-products-in-the-u-s-scientific-concepts-clinical-use-and-practical-considerations-december-10-2018/", "https://twitter.com/share?text=FDA Drug Topics: Biosimilar and Interchangeable Products in the U.S.: Scientific Concepts, Clinical Use, and Practical Considerations \u2013 December 10, 2018&url=https://prais.paho.org/es/fda-drug-topics-biosimilar-and-interchangeable-products-in-the-u-s-scientific-concepts-clinical-use-and-practical-considerations-december-10-2018/", "https://www.linkedin.com/shareArticle?mini=true&url=https://prais.paho.org/es/fda-drug-topics-biosimilar-and-interchangeable-products-in-the-u-s-scientific-concepts-clinical-use-and-practical-considerations-december-10-2018/%26source=", "https://plus.google.com/share?url=https://prais.paho.org/es/fda-drug-topics-biosimilar-and-interchangeable-products-in-the-u-s-scientific-concepts-clinical-use-and-practical-considerations-december-10-2018/", "https://prais.paho.org/es/fda-drug-topics-biosimilar-and-interchangeable-products-in-the-u-s-scientific-concepts-clinical-use-and-practical-considerations-december-10-2018/", "https://www.fda.gov/AboutFDA/WorkingatFDA/FellowshipInternshipGraduateFacultyPrograms/PharmacyStudentExperientialProgramCDER/ucm626386.htm", "https://prais.paho.org/es/category/inicio-mensajes/", "https://prais.paho.org/es/mexico-cofepris-libera-38-productos-con-cannabis-y-sus-derivados/", "https://www.facebook.com/sharer/sharer.php?u=https://prais.paho.org/es/mexico-cofepris-libera-38-productos-con-cannabis-y-sus-derivados/", "https://twitter.com/share?text=M\u00e9xico: COFEPRIS libera 38 productos con cannabis y sus derivados&url=https://prais.paho.org/es/mexico-cofepris-libera-38-productos-con-cannabis-y-sus-derivados/", "https://www.linkedin.com/shareArticle?mini=true&url=https://prais.paho.org/es/mexico-cofepris-libera-38-productos-con-cannabis-y-sus-derivados/%26source=", "https://plus.google.com/share?url=https://prais.paho.org/es/mexico-cofepris-libera-38-productos-con-cannabis-y-sus-derivados/", "https://prais.paho.org/es/mexico-cofepris-libera-38-productos-con-cannabis-y-sus-derivados/", "https://www.gob.mx/cofepris/articulos/liberan-38-productos-con-cannabis-y-sus-derivados-182739?idiom=es", "https://prais.paho.org/es/category/inicio-mensajes/", "https://prais.paho.org/es/anmat-3er-simposio-argentino-de-buenas-practicas-de-farmacovigilancia/", "https://www.facebook.com/sharer/sharer.php?u=https://prais.paho.org/es/anmat-3er-simposio-argentino-de-buenas-practicas-de-farmacovigilancia/", "https://twitter.com/share?text=ANMAT: 3er Simposio Argentino de Buenas Pr\u00e1cticas de Farmacovigilancia&url=https://prais.paho.org/es/anmat-3er-simposio-argentino-de-buenas-practicas-de-farmacovigilancia/", "https://www.linkedin.com/shareArticle?mini=true&url=https://prais.paho.org/es/anmat-3er-simposio-argentino-de-buenas-practicas-de-farmacovigilancia/%26source=", "https://plus.google.com/share?url=https://prais.paho.org/es/anmat-3er-simposio-argentino-de-buenas-practicas-de-farmacovigilancia/", "https://prais.paho.org/es/anmat-3er-simposio-argentino-de-buenas-practicas-de-farmacovigilancia/", "https://www.argentina.gob.ar/noticias/3er-simposio-argentino-de-buenas-practicas-de-farmacovigilancia", "https://prais.paho.org/en/category/rss/", "https://prais.paho.org/es/category/rss-es/", "https://prais.paho.org/pt/category/rss-pt/", "https://prais.paho.org/es/human-placenta-products-for-consumption-not-authorized-in-canada-may-pose-serious-health-risks/", "https://www.facebook.com/sharer/sharer.php?u=https://prais.paho.org/es/human-placenta-products-for-consumption-not-authorized-in-canada-may-pose-serious-health-risks/", "https://twitter.com/share?text=Human placenta products for consumption not authorized in Canada, may pose serious health risks&url=https://prais.paho.org/es/human-placenta-products-for-consumption-not-authorized-in-canada-may-pose-serious-health-risks/", "https://www.linkedin.com/shareArticle?mini=true&url=https://prais.paho.org/es/human-placenta-products-for-consumption-not-authorized-in-canada-may-pose-serious-health-risks/%26source=", "https://plus.google.com/share?url=https://prais.paho.org/es/human-placenta-products-for-consumption-not-authorized-in-canada-may-pose-serious-health-risks/", "https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/68368a-eng.php", "https://prais.paho.org/en/category/rss/", "https://prais.paho.org/es/category/rss-es/", "https://prais.paho.org/pt/category/rss-pt/", "https://prais.paho.org/es/eficacia-y-seguridad-de-ibrutinib-en-el-tratamiento-de-pacientes-con-diagnostico-de-linfoma-de-celulas-del-manto-con-al-menos-dos-lineas-de-tratamiento-previo/", "https://www.facebook.com/sharer/sharer.php?u=https://prais.paho.org/es/eficacia-y-seguridad-de-ibrutinib-en-el-tratamiento-de-pacientes-con-diagnostico-de-linfoma-de-celulas-del-manto-con-al-menos-dos-lineas-de-tratamiento-previo/", "https://twitter.com/share?text=Eficacia y seguridad de ibrutinib en el tratamiento de pacientes con diagn\u00f3stico de linfoma de c\u00e9lulas del manto, con al menos dos l\u00edneas de tratamiento previo&url=https://prais.paho.org/es/eficacia-y-seguridad-de-ibrutinib-en-el-tratamiento-de-pacientes-con-diagnostico-de-linfoma-de-celulas-del-manto-con-al-menos-dos-lineas-de-tratamiento-previo/", "https://www.linkedin.com/shareArticle?mini=true&url=https://prais.paho.org/es/eficacia-y-seguridad-de-ibrutinib-en-el-tratamiento-de-pacientes-con-diagnostico-de-linfoma-de-celulas-del-manto-con-al-menos-dos-lineas-de-tratamiento-previo/%26source=", "https://plus.google.com/share?url=https://prais.paho.org/es/eficacia-y-seguridad-de-ibrutinib-en-el-tratamiento-de-pacientes-con-diagnostico-de-linfoma-de-celulas-del-manto-con-al-menos-dos-lineas-de-tratamiento-previo/", "http://sites.bvsalud.org/redetsa/brisa/resource/?id=biblioref.referencesource.965704", "https://prais.paho.org/en/category/rss/", "https://prais.paho.org/es/category/rss-es/", "https://prais.paho.org/pt/category/rss-pt/", "https://prais.paho.org/es/eficacia-y-seguridad-de-l-asparaginasa-e-coli-pegilada-en-el-tratamiento-de-pacientes-con-leucemia-linfoblastica-aguda-que-presentan-hipersensibilidad-a-l-asparaginasa-e-coli-nativa-en-el-contexto/", "https://www.facebook.com/sharer/sharer.php?u=https://prais.paho.org/es/eficacia-y-seguridad-de-l-asparaginasa-e-coli-pegilada-en-el-tratamiento-de-pacientes-con-leucemia-linfoblastica-aguda-que-presentan-hipersensibilidad-a-l-asparaginasa-e-coli-nativa-en-el-contexto/", "https://twitter.com/share?text=Eficacia y seguridad de l-asparaginasa e. Coli pegilada en el tratamiento de pacientes con leucemia linfobl\u00e1stica aguda que presentan hipersensibilidad a l- asparaginasa e. Coli nativa, en el contexto de no disponibilidad de l-asparaginasa erwinia&url=https://prais.paho.org/es/eficacia-y-seguridad-de-l-asparaginasa-e-coli-pegilada-en-el-tratamiento-de-pacientes-con-leucemia-linfoblastica-aguda-que-presentan-hipersensibilidad-a-l-asparaginasa-e-coli-nativa-en-el-contexto/", "https://www.linkedin.com/shareArticle?mini=true&url=https://prais.paho.org/es/eficacia-y-seguridad-de-l-asparaginasa-e-coli-pegilada-en-el-tratamiento-de-pacientes-con-leucemia-linfoblastica-aguda-que-presentan-hipersensibilidad-a-l-asparaginasa-e-coli-nativa-en-el-contexto/%26source=", "https://plus.google.com/share?url=https://prais.paho.org/es/eficacia-y-seguridad-de-l-asparaginasa-e-coli-pegilada-en-el-tratamiento-de-pacientes-con-leucemia-linfoblastica-aguda-que-presentan-hipersensibilidad-a-l-asparaginasa-e-coli-nativa-en-el-contexto/", "http://sites.bvsalud.org/redetsa/brisa/resource/?id=biblioref.referencesource.965705", "https://prais.paho.org/es/author/freitasmpaho-org/page/403/", "https://prais.paho.org/es/author/freitasmpaho-org/", "https://prais.paho.org/es/author/freitasmpaho-org/page/403/", "https://prais.paho.org/es/author/freitasmpaho-org/page/405/", "https://prais.paho.org/es/author/freitasmpaho-org/page/567/", "https://prais.paho.org/es/author/freitasmpaho-org/page/405/", "https://prais.paho.org/es/category/rss-prais-es/", "https://prais.paho.org/es/landscaping/#respond", "https://prais.paho.org/es/landscaping/", "https://prais.paho.org/es/category/rss-prais-es/", "https://prais.paho.org/es/comite-de-expertos-de-la-oms-en-especificaciones-para-las-preparaciones-farmaceuticas-55o-informe/#respond", "https://prais.paho.org/es/comite-de-expertos-de-la-oms-en-especificaciones-para-las-preparaciones-farmaceuticas-55o-informe/", "https://prais.paho.org/es/category/rss-prais-es/", "https://prais.paho.org/es/ops-mantiene-recomendacion-de-utilizar-vacunas-covid-19-que-llegaran-por-covax-a-las-americas-pese-a-nuevas-variantes/#respond", "https://prais.paho.org/es/ops-mantiene-recomendacion-de-utilizar-vacunas-covid-19-que-llegaran-por-covax-a-las-americas-pese-a-nuevas-variantes/", "https://prais.paho.org/es/category/movies-es/", "https://prais.paho.org/es/los-sistemas-regulatorios-en-la-agenda-post-covid-19/#respond", "https://prais.paho.org/es/los-sistemas-regulatorios-en-la-agenda-post-covid-19/", "https://prais.paho.org/es/category/movies-es/", "https://prais.paho.org/es/episode-25-vaccines-explained/#respond", "https://prais.paho.org/es/episode-25-vaccines-explained/", "https://prais.paho.org/es/category/movies-es/", "https://prais.paho.org/es/28863-2/#respond", "https://prais.paho.org/es/28863-2/", "https://prais.paho.org/es/category/movies-es/", "https://prais.paho.org/es/los-sistemas-regulatorios-en-la-agenda-post-covid-19/#respond", "https://prais.paho.org/es/los-sistemas-regulatorios-en-la-agenda-post-covid-19/", "https://prais.paho.org/es/category/movies-es/", "https://prais.paho.org/es/episode-25-vaccines-explained/#respond", "https://prais.paho.org/es/episode-25-vaccines-explained/", "https://prais.paho.org/es/category/movies-es/", "https://prais.paho.org/es/28863-2/#respond", "https://prais.paho.org/es/28863-2/", "https://facebook.com/PAHOWHO", "https://twitter.com/pahowho", "https://instagram.com/opspaho", "https://www.linkedin.com/company/pan-american-health-organization", "https://youtube.com/pahopin", "https://www.flickr.com/photos/87642443@N05/", "https://prais.paho.org/es/feed", "https://prais.paho.org/es/inicio/wp-admin/nav-menus.php"]}